Dyne Therapeutics Inc. (NYSE: DYN) stock closed at 7.01 per share at the end of the most recent trading day (a 2.64% change compared to the prior day closing price) with a volume of 132.84K shares and market capitalization of 336.26M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 36 people. Dyne Therapeutics Inc. CEO is Joshua T. Brumm.

The one-year performance of Dyne Therapeutics Inc. stock is -68.61%, while year-to-date (YTD) performance is -41.04%. DYN stock has a five-year performance of -16.65%. Its 52-week range is between 4.3 and 22.92, which gives DYN stock a 52-week price range ratio of 11.87%

Dyne Therapeutics Inc. currently has a PE ratio of -2.20, a price-to-book (PB) ratio of 1.05, a price-to-sale (PS) ratio of -, a price to cashflow ratio of 3.50, a PEG ratio of 2.32, a ROA of -36.36%, a ROC of -36.69% and a ROE of -39.25%. The company’s profit margin is -14.58%, its EBITDA margin is 18.60%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Dyne Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.81 for the next earnings report. Dyne Therapeutics Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Dyne Therapeutics Inc. is Strong Buy (1), with a target price of $27.75, which is +326.27% compared to the current price. The earnings rating for Dyne Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Dyne Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Dyne Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 12.30, ATR14 : 0.60, CCI20 : 178.10, Chaikin Money Flow : 0.13, MACD : 0.16, Money Flow Index : 85.38, ROC : 42.19, RSI : 64.12, STOCH (14,3) : 95.02, STOCH RSI : 1.00, UO : 58.34, Williams %R : -4.98), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Dyne Therapeutics Inc. in the last 12-months were: Jonathan McNeill (Sold 1 755 shares of value $24 451 ), Joshua T. Brumm (Sold 11 393 shares of value $156 855 ), Oxana Beskrovnaya (Sold 2 137 shares of value $29 004 ), Richard William Scalzo (Sold 1 167 shares of value $16 344 ), Susanna High (Sold 3 216 shares of value $48 885 ), Wildon Farwell (Sold 6 257 shares of value $53 669 )